WASHINGTON--(BUSINESS WIRE)--RightEye LLC, a health technology company using eye tracking to revolutionize vision performance and patient care, announced today that it has acquired the exclusive rights to two internationally recognized eye movement tests that help doctors more accurately and objectively identify early stages of autism in children 12 to 40 months old, and aids in detecting Parkinson’s disease in patients of all ages. The tests, which are based on extensive clinical studies, help identify both disorders earlier and more accurately, which can lead to earlier and more appropriate intervention.
Pharnext Confirms its Continuous Support of the Hereditary Neuropathy Foundation to Increase Global Awareness of Charcot-Marie-Tooth Disease
PARIS--(EON: Enhanced Online News)--Regulatory News:Pharnext (Paris:ALPHA) (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today confirmed its continuous support of the Hereditary Neuropathy Foundation (HNF) at the occasion of the Charcot-Marie-Tooth (CMT) disease awareness month.CMT, as do many orphan diseases, suffers from a clear lack of awareness amongst the general public, the medical and research communities and health authorities. Pharnext’s support of HNF – initiated two years ago – is aimed at increasing awareness of this disease and strengthening the patient community to ensure: better and faster diagnosis of patients with CMT, optimal management of these patients and strong support of researchers and clinicians to ultimately find a cure for this debilitating group of inherited peripheral neuropathies.
European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy
Cabometyx™ (cabozantinib) is the first and only targeted therapy to improve Overall Survival (OS), Objective Response Rate (ORR), and Progression Free Survival (PFS) in RCC in METEOR randomized Phase 3 trial Cabometyx™ (cabozantinib) improves OS across all evaluated patient subgroups Cabometyx™ (cabozantinib) has a unique mechanism of action with the potential to overcome resistance to VEGFR tyrosine kinase inhibitors Paris, France, 14 September 2016 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced that the European Commission has approved Cabometyx™ (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx™ (cabozantinib) is the only single agent to demonstrate significant clinical benefits across all three efficacy endpoints (OS, PFS, ORR) in a phase 3 study in previously treated patients with RCC. This approval allows for the marketing of Cabometyx™ (cabozantinib) in previously treated advanced RCC in all 28 member states of the European Union, Norway and Iceland.
Researchers at Karolinska Institutet and the Feinstein Institute for Medical Research have discovered that the human immune system has a hitherto unknown role – blood pressure regulation. Collaborating with colleagues from Canada, they have found that a special kind of immune cell called acetylcholine-producing lymphocytes can regulate blood pressure in laboratory mice. The study, which is published in Nature Biotechnology , could open the way for new forms of treatment for hypertension.High blood pressure, or hypertension, is a crucial risk factor for premature death around the world. Despite this, hypertension often has indeterminable causes, although it has long been known that the neurotransmitter acetylcholine plays an important part in that it causes blood vessels to relax and regulates blood pressure by influencing the production of nitric oxide. By studying laboratory mice lacking a certain kind of immune cell called acetylcholine-producing lymphocytes, a research group at Karolinska Institutet and their colleagues at the Feinstein Institute for Medical Research in New York and the University Health Network in Toronto have discovered that these immune cells have a previously unknown function: to reduce the blood pressure.
New Data Affirm Strong Efficacy and Well-Characterized Safety Profile of TECFIDERA® in Both Clinical Studies and Real-World Setting
CAMBRIDGE, Mass.--(BUSINESS WIRE)--New real-world and clinical evidence demonstrates that TECFIDERA® (dimethyl fumarate) consistently delivered strong, sustained efficacy in newly-diagnosed and previously treated patients with relapsing-remitting multiple sclerosis (RRMS) and affirms its well-characterized safety profile in patients who have had up to nine years of treatment. Biogen (NASDAQ: BIIB) will present these data at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in London.“As we continue to gather both clinical and real-world data, evidence shows that TECFIDERA consistently demonstrates strong efficacy in reducing MS disease activity over the long term,” said Ralph Kern, M.D., senior vice president, Worldwide Medical, Biogen. “The findings presented at ECTRIMS confirm the results we observed in the TECFIDERA clinical trial program, further supporting its early use to improve outcomes for people living with MS.”
Merck KGaA, Darmstadt, Germany, Joins DiViNe Consortium to Address Low Yields, High Costs of Vaccine Purification Processes
Merck KGaA, Darmstadt, Germany, Joins DiViNe Consortium to Address Low Yields, High Costs of Vaccine Purification Processes• Five year project will create more cost effective purification program • Company to provide chromatographic expertiseDarmstadt, Germany, September 14, 2016 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, has joined the DiViNe project, a European consortium of six companies to address the biggest challenges facing the development, manufacture and delivery of vaccines.
Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions
DUBLIN and FORT WASHINGTON, Pa., Sept. 14, 2016 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Vitae Pharmaceuticals, Inc. (NASDAQ: VTAE), a clinical-stage biotechnology company, today announced that they have entered into a definitive agreement under which Allergan will acquire Vitae for .00 per share, in cash, for a total transaction value of approximately 9 million. The Boards of Directors of both companies have unanimously approved the transaction.
Miniaturized Device Now Available for Use in Patients with Unexplained Syncope and Stroke DUBLIN - Sept. 14, 2016 - Medtronic plc (NYSE: MDT) today announced it has received Ministry of Health, Labor and Welfare (MHLW) approval of the Reveal LINQ Insertable Cardiac Monitor (ICM) System in Japan. In addition, MHLW has granted reimbursement approval for Reveal LINQ as a result of work with the Japanese regulatory body. The device will be available in Japan beginning this month. The Reveal LINQ ICM System is the smallest insertable cardiac monitoring device available (~1 cc, or one-third the size of an AAA battery); it is designed to help physicians quickly and accurately diagnose irregular heartbeats. Placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest, the Reveal LINQ ICM is inserted using a minimally invasive procedure; its presence is often nearly undetectable to the naked eye once the incision has healed.
Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career
PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development & Medical Affairs, for Lilly's Oncology business on January 1, 2017. He will succeed Richard Gaynor, M.D., who will retire after a distinguished career at Lilly. Dr. Garraway is currently associate professor of medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, an associate physician at the Brigham and Women's Hospital, an Institute Member of the Broad Institute of MIT and Harvard, and an investigator of the Howard Hughes Medical Institute. He will report to Sue Mahony, Ph.D., Lilly senior vice president and president of Lilly Oncology. "We are pleased and honored to have Dr. Garraway join us at Lilly," Mahony said. "He has made a tremendous impact in his career and is recognized around the world as a leader in oncology. "We know he will provide keen insight and expertise—and will continue to advance Lilly's work in developing innovative new medicines to truly make life better for people with cancer around the world." Mahony praised Dr. Gaynor for his significant contributions to the discovery and development of cancer medicines. "Richard is known for scientific rigor and deep expertise in drug development, coupled with a personal warmth and care for patients that is truly inspiring," she said. "He is leaving a remarkable legacy at Lilly through his impact on the pipeline, people and patients."